Acadia Healthcare Co Bolsa (NASDAQ: ACHC)

Últimas noticias sobre Acadia Healthcare Co (NASDAQ:ACHC) Bolsa

Acadia Healthcare Co

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $76 to $43.

News

Price Target

Analyst Ratings

ACHC

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $43

5 analysts have shared their evaluations of Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $82.8, a high estimate of $94.00, and a low estimate of $64.00. Highlighting a 8.2% decrease, the current average has fallen from the previous average price target of $90.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1731960028_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acadia Healthcare Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Breaking Down Acadia Healthcare Co's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.7% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching 8.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Acadia Healthcare Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.28% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of 0.66, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 5 Analyst Evaluations For Acadia Healthcare Co

RBC Capital analyst Ben Hendrix maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and lowers the price target from $94 to $64.

RBC Capital Maintains Outperform on Acadia Healthcare Co, Lowers Price Target to $64

WIIM

Acadia Healthcare shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 guidance below estimates.

Earnings

Guidance

Acadia Healthcare Sees 2024 Revenue $3.150B-$3.165B Vs $3.204B Est.; Adj. EPS $3.35-$3.45 Per Share Vs $3.520 Est.

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares moved upwards by 28.8% to $4.2 during Wednesday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares increased by 11.21% to $6.25. The market value of their outstanding shares is at $877.9 million. The company's, Q3 earnings came out today. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock rose 10.79% to $0.9. The market value of their outstanding shares is at $32.8 million. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock rose 9.2% to $21.0. The market value of their outstanding shares is at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 7.56% to $2.7. The market value of their outstanding shares is at $9.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 7.5% to $1.29. The company's market cap stands at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares fell 16.8% to $39.0 during Wednesday's after-market session. The company's market cap stands at $4.0 billion. The company's, Q3 earnings came out today. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares decreased by 13.22% to $45.2. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock decreased by 12.77% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares declined by 7.43% to $1.87. The market value of their outstanding shares is at $7.1 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) stock decreased by 6.69% to $3.35. The company's market cap stands at $107.8 million. </li>
<li>Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) stock fell 6.31% to $3.93. The market value of their outstanding shares is at $162.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANIX

ATEC

CMAX

CORT

CTOR

ELDN

ESLA

NVST

TFFP

TNON

VERO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.90 by 1.11 percent. The company reported quarterly sales of $815.63 million which missed the analyst consensus estimate of $819.43 million by 0.46 percent. This is a 8.70 percent increase over sales of $750.33 million the same period last year.

Earnings Beats

Earnings Misses

Acadia Healthcare Co Q3 2024 Adj EPS $0.91 Beats $0.90 Estimate, Sales $815.63M Miss $819.43M Estimate

Acadia Healthcare shares are trading lower following a report indicating the Veterans Department is investigating the company for insurance fraud.

<a href="https://www.nytimes.com/2024/10/18/business/acadia-healthcare-veterans-affairs-investigation.html">https://www.nytimes.com/2024/10/18/business/acadia-healthcare-veterans-affairs-investigation.html</a>
The Veterans Affairs Department is investigating whether Acadia Healthcare, one of the country's largest chains of psychiatric hospitals, is defrauding government health insurance programs by holding patients longer than is medically necessary, according to three people with knowledge of the inquiry.
The investigation, led by the agency's inspector general, comes three weeks after <a href="https://www.nytimes.com/2024/09/27/business/acadia-federal-investigations.html">Acadia told investors</a> that it was facing scrutiny for its admissions practices from several other federal investigators, including prosecutors in Manhattan and a grand jury in Missouri. The company, which relies on government insurance programs like Medicare and Medicaid for much of its revenue, said it was also expecting to receive inquiries from the Securities and Exchange Commission and other agencies.
Acadia told investors that it was "fully cooperating with authorities and, at this time, cannot speculate on whether the outcome of these investigations will have any impact on its business or operations." The company has denied claims that it was improperly holding patients and has said that all decisions about care are made by licensed medical professionals.
The Veterans Affairs Department did not immediately respond to questions about the new investigation.
&nbsp;
<a href="https://www.nytimes.com/2024/09/01/business/acadia-psychiatric-patients-trapped.html">The New York Times reported</a> in September that Acadia was holding patients against their will in ways that appeared to violate state laws. The Times reported that some patients arrived at emergency rooms seeking routine mental health care but then were sent to Acadia facilities and locked in. The company's employees often held patients until their insurance coverage ran out, even when there was no medical justification.
The Times article was based on official complaints, court records and interviews with patients, as well as more than 50 current and former Acadia employees.
Last month, Acadia <a href="https://www.nytimes.com/2024/09/26/health/acadia-doj-settlement-fbi.html">agreed to pay</a> almost $20 million to settle Justice Department claims that the company had defrauded government health insurers by holding patients longer than medically necessary and admitting people who didn't need to be there. Acadia did not acknowledge wrongdoing in that case, which covered conduct from 2014 through 2017.
The fresh round of investigations are focused on recent events. The veterans agency is looking into whether Acadia billed insurance programs for patients who were stable enough to be released and did not need intensive inpatient care, according to two of the people with knowledge of the investigation, who requested anonymity because it has not been made public.
Several former Acadia employees in Georgia and Missouri have also recently been interviewed by agents from the F.B.I. and the inspector general's office of the Health and Human Services Department.

Legal

'Veterans Dept. Investigating Acadia Healthcare For Insurance Fraud; Several Federal Agencies Are Investigating Whether The Large Chain Of Psychiatric Hospitals Held Patients Without Medical Justification' - NY Times

Acadia Healthcare Acquires Three Opioid Treatment Clinics In South Carolina, Expanding Comprehensive Treatment Centers To The Palmetto State And Reaching 165 Locations Nationwide

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $86.8, a high estimate of $94.00, and a low estimate of $75.00. Highlighting a 0.91% decrease, the current average has fallen from the previous average price target of $87.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1728662436_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Acadia Healthcare Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Acadia Healthcare Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>Discovering Acadia Healthcare Co: A Closer Look</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>A Deep Dive into Acadia Healthcare Co's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Acadia Healthcare Co displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.85%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Acadia Healthcare Co's ROE stands out, surpassing industry averages. With an impressive ROE of 2.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadia Healthcare Co's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.4%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 10 Ratings For Acadia Healthcare Co

Keybanc analyst Matthew Gillmor initiates coverage on Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Sector Weight rating.

Initiation

Keybanc Initiates Coverage On Acadia Healthcare Co with Sector Weight Rating

<a href="https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340" title="https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340">https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340</a>

'Senator urges DOJ to investigate youth treatment centers after probe uncovers 'rampant abuse'' - NBC News

Cantor Fitzgerald analyst Sarah James reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and maintains $90 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Acadia Healthcare Co, Maintains $90 Price Target

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $83 to $76.

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $76

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday.
The Dow traded up 0.26% to 42,285.93 while the NASDAQ fell 0.59% to 18,083.01. The S&amp;P 500 also fell, dropping, 0.25% to 5,731.09.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 1.3% on Friday.
In trading on Friday, information technology shares fell by 1%.
Top Headline
The total number of active U.S. oil rigs fell by four to 484 rigs this week, Baker Hughes Inc reported
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares shot up 16% to $9.36 after the company announced it signed a $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 56% to $5.28. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were also up, gaining 12% to $9.75 after Keybanc raised its price target on the stock from $8 to $11.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 19% to $4.07. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 25% to $4.07 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 16% to $63.46 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $68.18 while gold traded down 0.9% at $2,670.50.
Silver traded down 1.4% to $31.88 on Friday, while copper fell 1% to $4.5930.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.47%, Germany's DAX climbed 1.22% and France's CAC 40 jumped 0.64%. Spain's IBEX 35 Index rose 0.12%, while London's FTSE 100 rose 0.43%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The US core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs fell by four to 484 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

IONQ

NVNO

ONCO

RKLB

SEEL

Crude Oil Rises; Onconetix Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 53.5% to $5.15 during Friday's regular session. The company's market cap stands at $3.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 31.77% to $0.6. The market value of their outstanding shares is at $29.1 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 22.72% to $1.89. The market value of their outstanding shares is at $11.1 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock moved upwards by 22.69% to $1.19. The market value of their outstanding shares is at $43.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 16.98% to $1.24. The company's market cap stands at $12.6 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares increased by 16.73% to $0.25. The company's market cap stands at $5.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares decreased by 27.0% to $1.49 during Friday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 24.45% to $3.4. The company's market cap stands at $45.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares decreased by 21.54% to $0.47. The market value of their outstanding shares is at $3.5 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 18.43% to $0.77. The company's market cap stands at $14.9 million. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 17.41% to $62.49. The company's market cap stands at $5.8 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 15.49% to $2.02. The company's market cap stands at $23.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INDP

MYNZ

PSTV

TOVX

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index surging more than 250 points on Friday.
The Dow traded up 0.66% to 42,452.85 while the NASDAQ fell 0.45% to 18,108.42. The S&amp;P 500 also fell, dropping, 0.07% to 5,741.34.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 1.4% on Friday.
In trading on Friday, information technology shares fell by 0.3%.
Top Headline
According to government data released Friday, the Personal Consumption Expenditures (PCE) Price Index increased by 2.2% in August compared to the same period last year. The reading was below the 2.3% analysts were expecting and a drop from July's 2.5%.
The core PCE, which excludes volatile food and energy prices, was 2.7% year-over-year in August, matching analyst expectations and 0.1% higher than July's number.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares shot up 19% to $9.56 after the company announced it signed a $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 64% to $5.57. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares were also up, gaining 11% to $10.59. Biomea Fusion disclosed that the FDA lifted its clinical hold on BMF-219 in Type 2 and Type 1 diabetes trials. Rodman &amp; Renshaw analyst Tony Butler upgraded Biomea Fusion from Neutral to Buy.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 12% to $4.39. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 22% to $3.50 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 25% to $56.60 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $67.16 while gold traded down 0.3% at $2,686.90.
Silver traded up 0.1% to $32.355 on Friday, while copper fell 0.3% to $4.6245.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX climbed 1.04% and France's CAC 40 jumped 0.49%. Spain's IBEX 35 Index rose 0.21%, while London's FTSE 100 rose 0.23%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The US core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Markets

BMEA

Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Root&nbsp;(ROOT)&nbsp;up 70.4...

Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats

Acadia Healthcare Company, Inc. (ACHC) Q3 2024 Earnings Call Transcript

Analyst Joanna Gajuk of Bank of America Securities reiterated a Buy rating on Acadia Healthcare (ACHC – Research Report), with a price target of $7...

Acadia Healthcare: Navigating Temporary Challenges with Promising Growth Prospects and Strong Fundamentals

Deutsche Bank lowered the firm's price target on Acadia Healthcare (ACHC) to $45 from $75 and keeps a Hold rating on the shares. The earnings repor...

Acadia Healthcare price target lowered to $45 from $75 at Deutsche Bank

Leerink Partners analyst Whit Mayo has maintained their bullish stance on ACHC stock, giving a Buy rating on November 1. Whit Mayo has given his Bu...

Acadia Healthcare: Long-term Growth Potential Amidst Operational Challenges

Hospital stocks could see negative impact under Trump

In a report released today, Ben Hendrix from RBC Capital maintained a Buy rating on Acadia Healthcare (ACHC – Research Report), with a price target...

RBC Capital Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)

Morgan Stanley lists hedge funds' largest Q3 ownership increases in Russell 1000 stocks

Barclays lowered the firm's price target on Acadia Healthcare (ACHC) to $43 from $76 and keeps an Overweight rating on the shares. The company note...

Acadia Healthcare price target lowered to $43 from $76 at Barclays

Barclays analyst Andrew Mok CFA maintained a Buy rating on Acadia Healthcare (ACHC – Research Report) today and set a price target of $43.00. The c...

Barclays Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)

ADUS

AMSC

ARDT

AZEK

BILL

BKNG

BRBR

CAVA

CFLT

CHRW

CIVI

COIN

COMP

CTLT

CVNA

DASH

DAWN

EBAY

ETSY

HOOD

JAKK

LITE

LMND

MPWR

MSFT

MTCH

OLED

PAYC

QGEN

RELY

ROKU

ROOT

SBUX

SOLV

TDOC

TWLO

WING

Press Releases

ACHC INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In ACHC To Contact Him Directly To Discuss Their Options

DEADLINE ALERT for ACHC, MAPS, TD, MYNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

ACHC INVESTOR NOTICE: Acadia Healthcare Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

ROSEN, A TOP-RANKED LAW FIRM, Encourages Acadia Healthcare Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ACHC

ACHC STOCK NEWS: Acadia Healthcare Stock Plummeted 16% - Contact BFA Law about its Class Action Lawsuit if You Suffered Losses (Nasdaq:ACHC)

Faruqi & Faruqi Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of the December 16, 2024 - ACHC

Faruqi & Faruqi Reminds Acadia Healthcare Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 16, 2024 - ACHC

ACHC Investors Have Opportunity to Lead Acadia Healthcare Company Inc. Securities Fraud Lawsuit

ACHC Investors Have Opportunity to Lead Acadia Healthcare Company, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ACADIA HEALTHCARE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Acadia Healthcare Company, Inc. - ACHC

Comments

Acadia Healthcare Co

Noticias

Últimas noticias sobre Acadia Healthcare Co (NASDAQ:ACHC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL